Sinopharm Group Co ( (HK:1099) ) has issued an announcement.
Sinopharm Group Co. Ltd. reported its unaudited financial results for the first quarter ending March 31, 2025. The company saw a 4.87% increase in revenue compared to the same period last year, reaching approximately RMB 12.71 billion. However, net profit attributable to shareholders slightly decreased by 0.10%. The net cash flow from operating activities was negative, indicating potential liquidity challenges. Despite these mixed results, the company’s total assets and equity attributable to shareholders showed modest growth, suggesting a stable financial position.
More about Sinopharm Group Co
Sinopharm Group Co. Ltd. operates in the pharmaceutical industry, focusing on the distribution and retail of pharmaceutical and healthcare products. It is a significant player in the Chinese market, with its subsidiary, China National Medicines Corporation Ltd. (SINOPHARM CNCM LTD), listed on the Shanghai Stock Exchange.
YTD Price Performance: -19.78%
Average Trading Volume: 2,115
Technical Sentiment Signal: Buy
Current Market Cap: $7.23B
Find detailed analytics on 1099 stock on TipRanks’ Stock Analysis page.